Exclusive: Roche exploring sale of diabetes device unit
NEW YORK (Reuters) - Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as...
Home > Reviews
All Stories
Cubist bid for Optimer before sale process began: sources
NEW YORK (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share,...
Hedge fund faces challenge in Tim Hortons shakeup bid
TORONTO/NEW YORK (Reuters) - Highfields Capital, a U.S. hedge fund agitating for change at Tim Hortons Inc, may have a hard time convincing institutional investors that the chain that says...
Deal maker Valeant reaches for biggest prize yet
WINNIPEG/NEW YORK (Reuters) - After five years and some 60 deals that have turned Valeant Pharmaceuticals International Inc into a stock market darling with a market capitalization of $22 billion,...
Banks find new niche as activist campaigns grow
NEW YORK (Reuters) - U.S. investment banks, many of which have reduced headcount in the face of shrinking profits, have found new opportunities in an unusual place, the growth in...
Banks find new niche as activist campaigns grow
NEW YORK (Reuters) - U.S. investment banks, many of which have reduced headcount in the face of shrinking profits, have found new opportunities in an unusual place, the growth in...
Exclusive: Nationwide, Reich & Tang to buy HighMark funds -sources
NEW YORK (Reuters) - Columbus, Ohio-based Nationwide Financial and New York-based Reich & Tang are buying UnionBanCal Corp's mutual fund business, three sources told Reuters on Tuesday. San Francisco-based UnionBanCal...
Dell’s board evaluates rival bids: source
A special committee of Dell Inc's board is evaluating separate takeover proposals from Blackstone Group and billionaire investor Carl Icahn to decide whether either or both are likely to trump...
Elan offers special dividend to fend off Royalty
DUBLIN/NEW YORK (Reuters) - Irish drugmaker Elan has sweetened the terms on offer to shareholders under a $3.25 billion disposal plan to try to stave off an approach for the...
Elan offers special dividend to fend off Royalty
DUBLIN/NEW YORK (Reuters) - Irish drugmaker Elan has sweetened the terms on offer to shareholders under a $3.25 billion disposal plan to try to stave off an approach for the...